Dr. Jon Wigginton, internationally recognized developer of immunotherapies, advisor to MPM Capital and CMO at Cullinan Oncology, to join UbiVac's Board
PORTLAND, OREGON, UNITED STATES, October 15, 2020 /EINPresswire.com/ — UbiVac Inc. is pleased to announce that Dr. Jon M. Wigginton, MD will join UbiVac’s Board of Directors. Dr. Wigginton had previously served on UbiVac’s scientific and business advisory boards. A physician and scientist, he is a leader in the development of combination immunotherapy drugs, and experienced in clinical trial design and oversight. Dr Wigginton’s skills and knowledge will be instrumental as UbiVac further develops its revolutionary DRibble Platform Vaccine technology.
“We are thrilled to have Dr. Jon M. Wigginton, an Internationally recognized physician-scientist who played a central role in the development of two breakthrough immunotherapies at Bristol Myers Squibb, and as CMO spearheaded the development of MacroGenics into a fully-integrated clinical immuno-oncology company, join our board," said Bernard A. Fox Ph,D., Founder, Chairman and CEO of UbiVac. "Dr. Wigginton’s experience will provide UbiVac critical insights as we roll out our next generation of immunotherapies based on our DRibble Platform Vaccine technology.”
"UbiVac’s innovative vaccine technology is the first to collect and concentrate hundreds of cancer antigens in a DC-targeted vaccine that is complexed with 20 immune stimulants. It is a revolutionary approach in cancer vaccines." said Dr. Wigginton: "I am thrilled to work with and help Bernie and his team advance their pipeline and clinical development."
With a career spanning almost 30 years divided between the NCI and industry, Dr. Wigginton is an experienced, knowledgeable, and respected leader in the field of immuno-oncology. He has overseen the translation of numerous molecules into the clinic including cytokines, checkpoint inhibitors, bispecific molecules, and various antibody combinations. Dr. Wigginton is an advisor to MPM Capital, a healthcare investment firm focused in life-science companies, and was recently appointed Chief Medical Officer of Cullinan Oncology, LLC after serving in the same position for MacroGenics. He was also the Therapeutic Area Head in Immuno-Oncology for Early Clinical Research at Bristol Myers Squibb and was a co-lead for the BMS International Immuno-Oncology Network (II-ON).
Additionally, Dr. Wigginton was Head of the Investigational Biologics Section, Center for Cancer Research, at the National Cancer Institute, NIH. There he led the effort on combination immunotherapy in pre-clinical and early stage clinical studies. He is a past president of the Society for the Immunotherapy of Cancer (SITC). Dr. Wigginton earned both his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
UbiVac is a privately held, clinical stage immunotherapy company engaged in the research and development of therapeutic vaccines to combat cancer. The company's innovative, first-in-class platform technology couples an off-the-shelf DC-targeted cancer vaccine with more than 100 cancer antigens for most adenocarcinomas and squamous cell cancers, plus multiple TLR/NOD agonists and DAMPs that are effective at inducing anti-cancer immune responses. UbiVac believes that DPV-001 is highly complementary to current and developing immunotherapy, chemotherapy and small molecule drug portfolios. UbiVac also has a pipeline of vaccines under development to prevent cancer in patients at high risk of developing disease and for those that have failed to respond to anti-PD-1/anti-PD-L1. Founded by Dr. Bernard A. Fox, Dr. Hong-Ming Hu, and Mr. Bernard A. Fox, III, in Portland, Oregon in 2005, UbiVac is a spin-out of the Robert W. Franz Cancer Center, Earle A. Chiles Research Institute at Providence Portland Medical Center.
To further the research and clinical development of its DRibble Platform Vaccine technology, UbiVac is currently raising equity funding from accredited investors. More information about the offering can be found at www.ubivac.com/investors.
There is a new paradigm for combating cancer
Source: EIN Presswire